<DOC>
	<DOCNO>NCT00180310</DOCNO>
	<brief_summary>Prospective , randomize , active-control , single blind , parallel two-arm multi-center clinical trial compare XIENCE V® Everolimus Eluting Coronary Stent System approve commercially available active control TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System . TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System manufacture Boston Scientific .</brief_summary>
	<brief_title>SPIRIT II : A Clinical Evaluation XIENCE V® Everolimus Eluting Coronary Stent System</brief_title>
	<detailed_description>The SPIRIT II trial randomize , single blind , active control , multi-center clinical evaluation . Subject eligibility criterion similar SPIRIT III enrollment duration overlap study . In study , 300 subject ( 3:1 randomization XIENCE V® EECSS : TAXUS™ PECSS enrol 31 site outside United States . The primary endpoint in-stent late loss 6 month . Secondary endpoint include clinical outcome month 1 , 6 , 9 month 1 , 2 , 3 , 4 5 year ; angiographic result 6 month 2 year ; IVUS result 6 month 2 year . Follow-up 3 year currently available .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>De novo Target lesion ( ) must locate native epicardial vessel diameter 2.25 mm 4.25 mm visual estimate The target lesion ( ) must major artery branch visually estimate stenosis &gt; = 50 % &lt; 100 % TIMI flow &gt; = 1 Nonstudy , percutaneous intervention lesion nontarget vessel allow do &gt; = 90 day prior index procedure plan do &gt; 9 month index procedure De novo target lesion ( ) locate major epicardial vessel side branch previously treat type percutaneous intervention ( e.g. , balloon angioplasty , stent , cut balloon , atherectomy ) &lt; 9 month prior index procedure Target lesion ( ) restenotic previous intervention Target lesion ( ) locate major epicardial vessel previously treat brachytherapy Target vessel ( ) contain visible thrombus Patient high probability procedure predilatation , stenting postdilatation require time index procedure treatment target vessel ( e.g . atherectomy , cut balloon brachytherapy ) Patient additional clinically significant lesion ( ) ( &gt; 50 % diameter stenosis ) target vessel side branch intervention within 9 month index procedure may require</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>drug elute stent</keyword>
	<keyword>stent</keyword>
	<keyword>angioplasty</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>total coronary occlusion</keyword>
	<keyword>coronary artery restenosis</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>vascular disease</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>coronary artery stenosis</keyword>
</DOC>